This expert panel will explore how Australia, Taiwan, and South Korea provide a strategic advantage in conducting early, mid, and late-phase oncology trials, offering speed, cost efficiency, and global scalability.
As regulatory uncertainty grows in the United States, US biotechs are increasingly looking to Australia as a stable and predictable launchpad for early-phase clinical trials.
Avance Clinical has further strengthened its presence in Asia with the opening of an office in Taipei, Taiwan.
Avance Clinical is pleased to announce the signing of four Memorandums of Understanding (MOUs) with key clinical trial sites in Taiwan this week.
The success of a biotech drug development program often depends on the relationship it forms with its Clinical Research Organization (CRO) partner.
For early-stage biotech companies, securing funding is often a significant challenge due to the complex and costly nature of drug development.
For early-stage biotech companies, securing funding is often a significant challenge due to the complex and costly nature of drug development.
Avance Clinical, a leading global CRO specializing in clinical trials for the biotech sector, has won the prestigious 2024 Frost & Sullivan Best Practices Customer Value Leadership Award for Global Biotech CRO Excellence.
Avance Clinical is thrilled to announce that it has again been named as a winner in the prestigious South Australian Premier’s Business and Export Awards 2024. This honor underscores Avance Clinical’s continued commitment to driving innovation and delivering world-class clinical trial solutions to the global ...
Avance Clinical is excited to announce that our Chief Operating Officer, Ben Edwards, will be attending the Clinical Operations Retreat for Executives (CORE) East Summit in Cape Cod this October.
Avance Clinical is a full-service Contract Research Organization (CRO) with clinical operations in Australia, New Zealand, Asia, North America, and Europe.
Level 22, 91 King William Street
Adelaide, SA
Australia 5000
Phone: +61 8 8249 4788
For all media enquiries: media@avancecro.com